Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 8/20 | 0.62 |
| ▸ | NAALAD2 | Q9Y3Q0 | 5/20 | 0.62 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.62 |
| ▸ | GGH | Q92820 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | FNTA | P49354 | 2/20 | 0.43 |
| ▸ | FNTB | P49356 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2552007 | 1.00 | FOLH1 (0.62) | FOLH1NAALAD2RIMKLAGGHGAA | |
| SCHEMBL29538498 | 0.85 | FOLH1 (0.58) | FOLH1NAALAD2RIMKLAGGHGAA | |
| SCHEMBL18876678 | 0.84 | NOD1 (0.46) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL21911518 | 0.84 | FOLH1 (0.56) | FOLH1NAALAD2RIMKLAGGH | |
| SCHEMBL8738364 | 0.82 | FPR2 (0.44) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL23786254 | 0.82 | FOLH1 (0.64) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL26830758 | 0.82 | FOLH1 (0.64) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL28428784 | 0.81 | FOLH1 (0.53) | FOLH1NAALAD2RIMKLAGGH | |
| SCHEMBL28428786 | 0.81 | FOLH1 (0.53) | FOLH1NAALAD2RIMKLAGGH | |
| SCHEMBL29538289 | 0.81 | FOLH1 (0.53) | FOLH1NAALAD2RIMKLAGGH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3473249-A1 | CROSSLINKABLE DENDRIMERS | Wayne State University (US) | 2019-04-24 | — | — | EP | claimed |
| US-20170028075-A1 | INJECTABLE DENDRIMER HYDROGEL NANOPARTICLES | Ashvattha Therapeutics, Inc. | 2017-02-02 | — | — | US | claimed |
| US-9526794-B2 | Injectable dendrimer hydrogel nanoparticles | WAYNE STATE UNIVERSITY (US) | 2016-12-27 | — | — | US | claimed |
| US-20130136697-A1 | INJECTABLE DENDRIMER HYDROGEL NANOPARTICLES | NATIONAL INSTITUTES OF HEALTH (US) | 2013-05-30 | — | — | US | claimed |
| EP-2552458-A1 | INJECTABLE DENDRIMER HYDROGEL NANOPARTICLES | Wayne State University (US) | 2013-02-06 | — | — | EP | claimed |
| WO-2011123591-A1 | INJECTABLE DENDRIMER HYDROGEL NANOPARTICLES | WAYNE STATE UNIVERSITY (US) | 2011-10-06 | — | — | WO | claimed |
| US-20250289842-A1 | Processes for Making NAG-25, a Carbohydrate Targeting Moiety, and its Intermediates | AMGEN INC. | 2025-09-18 | — | — | US | disclosed |
| EP-4519278-A1 | PROCESSES FOR MAKING NAG-25, A CARBOHYDRATE TARGETING MOIETY, AND ITS INTERMEDIATES | Amgen Inc. (US) | 2025-03-12 | — | — | EP | disclosed |
| CN-119562958-A | Methods for preparing NAG-25 carbohydrate targeting moieties and intermediates thereof | 安进公司 | 2025-03-04 | — | — | CN | disclosed |
| WO-2023215306-A1 | PROCESSES FOR MAKING NAG-25, A CARBOHYDRATE TARGETING MOIETY, AND ITS INTERMEDIATES | AMGEN INC. (US) | 2023-11-09 | — | — | WO | disclosed |
| WO-2023215306-A1 | PROCESSES FOR MAKING NAG-25, A CARBOHYDRATE TARGETING MOIETY, AND ITS INTERMEDIATES | AMGEN INC. (US) | 2023-11-09 | — | — | WO | disclosed |
| US-11446238-B2 | Injectable dendrimer hydrogel nanoparticles | WAYNE STATE UNIVERSITY (US) | 2022-09-20 | — | — | US | disclosed |
| EP-3473249-A1 | CROSSLINKABLE DENDRIMERS | Wayne State University (US) | 2019-04-24 | — | — | EP | disclosed |
| WO-2011123591-A1 | INJECTABLE DENDRIMER HYDROGEL NANOPARTICLES | WAYNE STATE UNIVERSITY (US) | 2011-10-06 | — | — | WO | disclosed |
| US-20070037821-A1 | Nitrosated glutamic acid compounds, compositions and methods of use | NITROMED, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| EP-1673384-A4 | NITROSATED GLUTAMIC ACID COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED INC (US) | 2007-02-07 | — | — | EP | disclosed |
| EP-1673384-A2 | NITROSATED GLUTAMIC ACID COMPOUNDS, COMPOSITIONS AND METHODS OF USE | Nitromed, Inc. (US) | 2006-06-28 | — | — | EP | disclosed |
| WO-2005030135-A2 | NITROSATED GLUTAMIC ACID COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2005-04-07 | — | — | WO | disclosed |
| US-6867316-B2 | Platinum(II) complexes of N-substituted amino dicarboxylates and the preparation method thereof | BOARD OF TRUSTEES, EWHA WOMANS UNIVERSITY (KR) | 2005-03-15 | — | — | US | disclosed |
| US-20040162342-A1 | Platinum(II) complexes of N-substituted amino dicarboxylates and the preparation method thereof | BOARD OF TRUSTEES, EWHA WOMANS UNIVERSITY (KR) | 2004-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250289842-A1 | Processes for Making NAG-25, a Carbohydrate Targeting Moiety, and its Intermediates | ENGASE, MAN2B2, GALNT2 | FOLH1 85/4885NAALAD2 37/4885RIMKLA 703/4885 |
| US-20040162342-A1 | Platinum(II) complexes of N-substituted amino dicarboxylates and the preparation method thereof | DAO, DDO, PRMT1 | FOLH1 348/4885NAALAD2 671/4885RIMKLA 514/4885 |
| US-20170028075-A1 | INJECTABLE DENDRIMER HYDROGEL NANOPARTICLES | PAM, UACA, FLT1 | FOLH1 3470/4885NAALAD2 2213/4885RIMKLA 2047/4885 |
| US-20130136697-A1 | INJECTABLE DENDRIMER HYDROGEL NANOPARTICLES | UACA, PAM, JAK3 | FOLH1 2813/4885NAALAD2 2726/4885RIMKLA 2369/4885 |
| US-11446238-B2 | Injectable dendrimer hydrogel nanoparticles | PAM, UACA, FLT1 | FOLH1 3470/4885NAALAD2 2213/4885RIMKLA 2047/4885 |
| US-20070037821-A1 | Nitrosated glutamic acid compounds, compositions and methods of use | GLS, NOS2, NOS1 | FOLH1 112/4885NAALAD2 164/4885RIMKLA 172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.